Page last updated: 2024-10-28
fasudil and Fibrosis
fasudil has been researched along with Fibrosis in 19 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "This research aimed to the study influence of fasudil (FAS) on myocardial fibrosis in rats with diabetes mellitus (DM) via the transforming growth factor-beta 1 (TGF-β1)/ small mothers against decapentaplegic (Smad) signaling pathway." | 8.31 | Fasudil attenuates myocardial fibrosis in rats with diabetes mellitus via TGF-β1/Smad signaling pathway. ( Liu, Y; Song, J; Su, F; Wang, F; Zhang, P, 2023) |
| "We hypothesis that Rho kinase inhibitor fasudil ameliorates osteoporosis following myocardial infarction (MI) by regulating cardiac calcitonin secretion." | 8.12 | Fasudil Ameliorates Osteoporosis Following Myocardial Infarction by Regulating Cardiac Calcitonin Secretion. ( Xiang, C; Xu, M; Zhang, D; Zhu, Y, 2022) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 7.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "Recent evidence indicates that the GTPase activated Rho/Rho-kinase pathway contributes angiotensin II-induced cardiac hypertrophy and vascular remodeling." | 7.73 | Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. ( Choy, DF; da Cunha, V; Dole, WP; Halks-Miller, M; Johns, A; Li, W; Light, DR; Mahmoudi, M; Martin-McNulty, B; Schroeder, M; Vincelette, J; Wang, YX, 2005) |
| "This study was designed to investigate possible effects of the Rho-kinase inhibitor, fasudil, on the progression of renal failure in rats with unilateral ureteral obstruction." | 7.71 | Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. ( Asano, T; Hitomi, A; Ikegaki, I; Sato, N; Satoh, S; Shimokawa, H; Shiraiwa, K; Yamaguchi, T, 2002) |
| "Renal fibrosis is the major cause of chronic kidney disease, and the Rho/Rho-associated coiled-coil kinase (ROCK) signaling cascade is involved in the renal fibrotic processes." | 5.42 | Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction. ( Baba, I; Egi, Y; Kakimoto, T; Suzuki, K; Utsumi, H, 2015) |
| " A selective Rho-kinase inhibitor, fasudil, has recently been shown to improve renal damage resulting from hypertensive glomerulosclerosis, unilateral ureteral obstruction (for interstitial renal fibrosis) and subtotal nephrectomy." | 4.83 | Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. ( Hayashi, K; Homma, K; Kanda, T; Saruta, T; Sugano, N; Wakino, S, 2006) |
| "This research aimed to the study influence of fasudil (FAS) on myocardial fibrosis in rats with diabetes mellitus (DM) via the transforming growth factor-beta 1 (TGF-β1)/ small mothers against decapentaplegic (Smad) signaling pathway." | 4.31 | Fasudil attenuates myocardial fibrosis in rats with diabetes mellitus via TGF-β1/Smad signaling pathway. ( Liu, Y; Song, J; Su, F; Wang, F; Zhang, P, 2023) |
| "We hypothesis that Rho kinase inhibitor fasudil ameliorates osteoporosis following myocardial infarction (MI) by regulating cardiac calcitonin secretion." | 4.12 | Fasudil Ameliorates Osteoporosis Following Myocardial Infarction by Regulating Cardiac Calcitonin Secretion. ( Xiang, C; Xu, M; Zhang, D; Zhu, Y, 2022) |
| " Fasudil can restrain EMT induced by PTH; this conclusion provides experimental data for the application of fasudil in the clinical prevention and treatment of renal fibrosis." | 3.85 | The influence of fasudil on renal proximal tubular cell epithelial-mesenchymal transition induced by parathormone. ( Cui, T; Gao, Z; Li, Z; Zhang, H; Zhu, W, 2017) |
| " We develop and utilize a glyoxylate induced mouse model of kidney calcium oxalate crystal deposition for studying the pharmacological effects of fasudil, a Rho associated protein kinase (ROCK) specific inhibitor, on the kidney injury and fibrosis caused by calcium oxalate crystallization and deposition." | 3.81 | Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice. ( Chen, W; Ding, J; Guo, Z; Hu, H; Jia, M; Yin, J, 2015) |
| " Further, perivascular and myocardial fibrosis, arterial intimal thickening were assessed by histology, and capillary density, nitrotyrosine and ROCK1/2 expressions were evaluated by immunohistochemical staining." | 3.79 | Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation. ( Edgley, AJ; Fujii, Y; Jenkins, MJ; Joshi, M; Kelly, DJ; Pearson, JT; Schwenke, DO; Shirai, M; Sonobe, T; Tsuchimochi, H; Umetani, K; Waddingham, MT; Yoshimoto, M, 2013) |
| " The present study was designed to examine the effect of fasudil, a Rho-kinase (ROCK) inhibitor, on myocardial remodeling and underlying mechanisms in pressure overload and myocardial infarction (MI) mice." | 3.78 | Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: role of TGF-β1-TAK1. ( Guo, Y; Li, Q; Li, X; Liu, G; Xu, Y, 2012) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 3.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "Recent evidence indicates that the GTPase activated Rho/Rho-kinase pathway contributes angiotensin II-induced cardiac hypertrophy and vascular remodeling." | 3.73 | Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. ( Choy, DF; da Cunha, V; Dole, WP; Halks-Miller, M; Johns, A; Li, W; Light, DR; Mahmoudi, M; Martin-McNulty, B; Schroeder, M; Vincelette, J; Wang, YX, 2005) |
| "This study was designed to investigate possible effects of the Rho-kinase inhibitor, fasudil, on the progression of renal failure in rats with unilateral ureteral obstruction." | 3.71 | Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. ( Asano, T; Hitomi, A; Ikegaki, I; Sato, N; Satoh, S; Shimokawa, H; Shiraiwa, K; Yamaguchi, T, 2002) |
| "Renal fibrosis is the major cause of chronic kidney disease, and the Rho/Rho-associated coiled-coil kinase (ROCK) signaling cascade is involved in the renal fibrotic processes." | 1.42 | Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction. ( Baba, I; Egi, Y; Kakimoto, T; Suzuki, K; Utsumi, H, 2015) |
| "Fasudil treatment notably attenuates renal interstitial fibrosis in diabetic rats." | 1.36 | The influence of fasudil on the epithelial-mesenchymal transdifferentiation of renal tubular epithelial cells from diabetic rats. ( Jia, R; Tu, Y; Wu, G, 2010) |
Research
Studies (19)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 10 (52.63) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Xiang, C | 1 |
| Zhu, Y | 1 |
| Xu, M | 1 |
| Zhang, D | 1 |
| Zhang, P | 1 |
| Wang, F | 1 |
| Song, J | 1 |
| Su, F | 1 |
| Liu, Y | 1 |
| Han, Z | 1 |
| Wang, Z | 1 |
| Song, C | 1 |
| Sheng, J | 1 |
| Niu, X | 1 |
| Qi, P | 1 |
| Gao, Z | 1 |
| Zhu, W | 1 |
| Zhang, H | 1 |
| Li, Z | 1 |
| Cui, T | 1 |
| Matoba, K | 1 |
| Kawanami, D | 1 |
| Okada, R | 1 |
| Tsukamoto, M | 1 |
| Kinoshita, J | 1 |
| Ito, T | 1 |
| Ishizawa, S | 1 |
| Kanazawa, Y | 1 |
| Yokota, T | 1 |
| Murai, N | 1 |
| Matsufuji, S | 1 |
| Takahashi-Fujigasaki, J | 1 |
| Utsunomiya, K | 1 |
| Pearson, JT | 1 |
| Jenkins, MJ | 1 |
| Edgley, AJ | 1 |
| Sonobe, T | 1 |
| Joshi, M | 1 |
| Waddingham, MT | 1 |
| Fujii, Y | 1 |
| Schwenke, DO | 1 |
| Tsuchimochi, H | 1 |
| Yoshimoto, M | 1 |
| Umetani, K | 1 |
| Kelly, DJ | 1 |
| Shirai, M | 1 |
| Hu, H | 1 |
| Chen, W | 1 |
| Ding, J | 1 |
| Jia, M | 1 |
| Yin, J | 1 |
| Guo, Z | 1 |
| Baba, I | 1 |
| Egi, Y | 1 |
| Utsumi, H | 1 |
| Kakimoto, T | 1 |
| Suzuki, K | 1 |
| Kagiyama, S | 1 |
| Matsumura, K | 1 |
| Goto, K | 1 |
| Otsubo, T | 1 |
| Iida, M | 1 |
| Wu, G | 1 |
| Tu, Y | 1 |
| Jia, R | 1 |
| Guo, P | 1 |
| Wu, C | 1 |
| Masaki, T | 1 |
| Mori, H | 1 |
| Nishiyama, A | 1 |
| Ho, TJ | 1 |
| Huang, CC | 1 |
| Huang, CY | 1 |
| Lin, WT | 1 |
| Li, Q | 1 |
| Xu, Y | 1 |
| Li, X | 1 |
| Guo, Y | 1 |
| Liu, G | 1 |
| Satoh, Si | 1 |
| Ikegaki, I | 2 |
| Toshima, Y | 1 |
| Watanabe, A | 1 |
| Asano, T | 2 |
| Shimokawa, H | 3 |
| Satoh, S | 1 |
| Yamaguchi, T | 1 |
| Hitomi, A | 1 |
| Sato, N | 1 |
| Shiraiwa, K | 1 |
| Hattori, T | 1 |
| Higashi, M | 1 |
| Hiroki, J | 1 |
| Mukai, Y | 1 |
| Tsutsui, H | 1 |
| Kaibuchi, K | 1 |
| Takeshita, A | 1 |
| Wang, YX | 1 |
| da Cunha, V | 1 |
| Martin-McNulty, B | 1 |
| Vincelette, J | 1 |
| Li, W | 1 |
| Choy, DF | 1 |
| Halks-Miller, M | 1 |
| Mahmoudi, M | 1 |
| Schroeder, M | 1 |
| Johns, A | 1 |
| Light, DR | 1 |
| Dole, WP | 1 |
| Nishikimi, T | 1 |
| Matsuoka, H | 1 |
| Hayashi, K | 1 |
| Wakino, S | 1 |
| Kanda, T | 1 |
| Homma, K | 1 |
| Sugano, N | 1 |
| Saruta, T | 1 |
Reviews
2 reviews available for fasudil and Fibrosis
| Article | Year |
|---|---|
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Collagen; Disease Models, An | 2006 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Cyclin-Dependent Kinase Inhi | 2006 |
Other Studies
17 other studies available for fasudil and Fibrosis
| Article | Year |
|---|---|
Fasudil Ameliorates Osteoporosis Following Myocardial Infarction by Regulating Cardiac Calcitonin Secretion.
Topics: Animals; Calcitonin; Fibrosis; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Osteoporo | 2022 |
Fasudil attenuates myocardial fibrosis in rats with diabetes mellitus via TGF-β1/Smad signaling pathway.
Topics: Animals; Cardiomyopathies; Collagen; Diabetes Mellitus; Fibrosis; Interleukin-1; Interleukin-6; Rats | 2023 |
Fasudil suppresses renal fibrosis in diabetic rats through PI3K/AKT signaling pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Fibrosis; Kidney Diseases; Phosphatidylinositol 3-Kinases; | 2023 |
The influence of fasudil on renal proximal tubular cell epithelial-mesenchymal transition induced by parathormone.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Antigens, CD; Cadherins; Cell Line; Disease P | 2017 |
Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Albuminuria; Animals; Diabetes Mellitus, Type 2; Diab | 2013 |
Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Angiography; Coronary Circulation; | 2013 |
Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Apoptosis; Cadherins; Calcium Oxalat | 2015 |
Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Cell Line; Cell Movement; Collagen T | 2015 |
Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Blood Pressure; Eplerenone; Fib | 2010 |
The influence of fasudil on the epithelial-mesenchymal transdifferentiation of renal tubular epithelial cells from diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylglucosamine; Actins; Animals; beta Catenin; Blo | 2010 |
Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Antihypertensive Agents; Biomar | 2011 |
Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bi | 2012 |
Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: role of TGF-β1-TAK1.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Atrial Natriuretic Factor; Blotting, Western | 2012 |
Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomyopathies; Chronic Disease; Disease M | 2002 |
Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Chemotaxis; Dose-Response Relationship, Drug | 2002 |
Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; DNA-Binding Proteins; Drug Administration Sc | 2004 |
Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Apolipoproteins E; Atrial Na | 2005 |